AMGN
Amgen Inc. · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.52M | $603.13M | n/a | −2 |
| Q2 2026 | 169 | -1 | 364.70M | $131.99B | +5 | −7 |
| Q1 2026 | 174 | -2 | 366.40M | $128.82B | +4 | −7 |
| Q4 2025 | 175 | 0 | 394.29M | $128.98B | +2 | −1 |
| Q3 2025 | 26 | 0 | 206.42M | $58.23B | n/a | −1 |
| Q2 2025 | 24 | +1 | 183.25M | $51.15B | +2 | −1 |
| Q1 2025 | 20 | -2 | 81.79M | $25.47B | n/a | −2 |
| Q4 2024 | 22 | +2 | 74.78M | $19.48B | +2 | n/a |
| Q3 2024 | 19 | -1 | 39.65M | $12.76B | +1 | −2 |
| Q2 2024 | 20 | n/a | 39.58M | $12.36B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 1.08M | +182.4% | $455.26M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 340.32K | -26.7% | $109.05M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 95.27K | -7.8% | $38.81M | 0.1% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Robeco Institutional Asset… | $210.05M | was 0.3% |
| Assetmark, Inc | $90.00M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3,100 holders, 420.54M shares, $144.29B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.25K sh · $521,365
Officer · 2.00K sh · $825,134
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology